{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=edoxaban&page=2",
    "query": {
      "intervention": "edoxaban",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=edoxaban&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T20:13:59.247Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00107900",
      "title": "Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthroplasty, Replacement, Hip",
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "DU-176b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 606,
      "start_date": "2005-01",
      "completion_date": "2005-12",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107900"
    },
    {
      "nct_id": "NCT04192916",
      "title": "Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "DOACs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 442,
      "start_date": "2019-09-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04192916"
    },
    {
      "nct_id": "NCT01662908",
      "title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "edoxaban tosylate",
          "type": "DRUG"
        },
        {
          "name": "enoxaparin/unfractionated heparin",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2012-08",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 29,
      "location_summary": "Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01662908"
    },
    {
      "nct_id": "NCT03271450",
      "title": "The DARE Warfarin CER Study",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Deep Venous Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Dabigatran: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Apixaban: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Apixaban: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Apixaban: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 416000,
      "start_date": "2017-07-01",
      "completion_date": "2021-10-30",
      "has_results": false,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03271450"
    },
    {
      "nct_id": "NCT03310021",
      "title": "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Andexanet alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 108,
      "start_date": "2017-08-28",
      "completion_date": "2019-08-13",
      "has_results": true,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03310021"
    },
    {
      "nct_id": "NCT04191928",
      "title": "Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreas Cancer",
        "DVT",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-03-03",
      "completion_date": "2021-09-01",
      "has_results": false,
      "last_update_posted_date": "2021-12-23",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191928"
    },
    {
      "nct_id": "NCT01999179",
      "title": "Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thrombosis",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Heparin, Low-Molecular-Weight, or direct oral anticoagulants",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2014-06",
      "completion_date": "2022-04-26",
      "has_results": true,
      "last_update_posted_date": "2022-05-18",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999179"
    },
    {
      "nct_id": "NCT04979780",
      "title": "Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Treatment of Venous Thromboembolism in Cancer Patients",
        "Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Low molecular weight heparin (LMWH)",
          "type": "DRUG"
        },
        {
          "name": "Direct Oral Anticoagulants (DOAC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3708,
      "start_date": "2021-07-20",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Connecticut",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04979780"
    },
    {
      "nct_id": "NCT04684212",
      "title": "Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Left Atrial Appendage Thrombosis",
        "CVA"
      ],
      "interventions": [
        {
          "name": "LAmbre PlusTM Left Atrial Appendage Closure System",
          "type": "DEVICE"
        },
        {
          "name": "Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brian O'Neill MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-06-01",
      "completion_date": "2024-07-11",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684212"
    },
    {
      "nct_id": "NCT02561897",
      "title": "EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Edoxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Electrophysiology Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2015-12",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2020-06-30",
      "last_synced_at": "2026-09-21T20:13:59.247Z",
      "location_count": 1,
      "location_summary": "Warren Township, New Jersey",
      "locations": [
        {
          "city": "Warren Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561897"
    }
  ]
}